Catalyst Pharmaceutical Inc.
CPRXCatalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. The company's flagship product is Firdapse, used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting nerve-muscle communication. Catalyst is dedicated to advancing treatments for patients with rare conditions through innovative research and development.
Company News
Italian pharmaceutical company Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for approximately $4.1 billion USD ($3.5 billion EUR). The deal strengthens Angelini Pharma's global presence in brain health and rare diseases while expanding into the U.S. market. Blackstone will invest €1 billion in preferred equity, and ...
Angelini Pharma has agreed to acquire biopharmaceutical company Catalyst Pharmaceuticals for $4.1 billion, or $31.50 per share. The deal was unanimously approved by both boards. Catalyst also resolved patent litigation related to its rare disease drug Firdapse.
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at approximately $4.1 billion (€3.5 billion). The acquisition marks Angelini Pharma's entry into the U.S. market and strengthens its focus on brain health and rare diseases. The deal is expected to close in Q3 2026, subject to stockh...
Catalyst Pharmaceuticals and licensor SERB S.A. have settled patent litigation with Hetero Labs regarding generic FIRDAPSE (amifampridine). Under the settlement, Hetero will not market its generic version in the U.S. before January 2035 if approved by the FDA. This resolves all pending FIRDAPSE patent litigation for Catalyst, following similar se...
Catalyst Pharmaceuticals (CPRX) trades at a 20-33% discount to pharma peers with a 7.5% free cash flow yield. The company's valuation is fairly valued to slightly undervalued at $24.50, with probability-weighted fair value around $29. The key binary catalyst is the Hetero litigation outcome expected in 2026—a win could push fair value to $28-32...
